Merck & Co Stock

Merck & Co Debt

The Debt of Merck & Co (MRK) as of Sep 15, 2026 is 49.63 B USD. In the previous year, Debt was 37.11 B USD — a change of 33.74% (higher).

Debt

49.63 BUSD

YoY

33.74%

Last updated:

In 2026, Merck & Co's total debt was 49.63 B USD, a 33.74% change from the 37.11 B USD total debt recorded in the previous year.

The Merck & Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
25.11 B USD
Jan 1, 2019
26.35 B USD
Jan 1, 2020
31.79 B USD
Jan 1, 2021
33.10 B USD
Jan 1, 2022
30.69 B USD
Jan 1, 2023
35.06 B USD
Jan 1, 2024
37.11 B USD
Jan 1, 2025
49.63 B USD
The Merck & Co Debt history
YEARDebtYoY
49.63 BUSD+33.74%
37.11 BUSD+5.87%
35.06 BUSD+14.22%
30.69 BUSD-7.28%
33.10 BUSD+4.12%
31.79 BUSD+20.67%
26.35 BUSD+4.91%
25.11 BUSD+2.88%
24.41 BUSD-1.74%
24.84 BUSD-5.94%
26.41 BUSD+23.40%
21.40 BUSD
Access this data via the Eulerpool API

Merck & Co Stock analysis

What does Merck & Co do? The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards. Merck & Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Merck & Co's Debt Structure

Merck & Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Merck & Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Merck & Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Merck & Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Merck & Co stock

Debt of Merck & Co is 49.63 B USD in 2026.

Debt of Merck & Co changed from 37.11 B USD to 49.63 B USD, representing a 33.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Merck & Co since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Merck & Co historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Merck & Co

All Key Metrics — Merck & Co